PM
UTHR icon

Prosight Management’s United Therapeutics UTHR Stock Holding History

Prosight Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-15,000
Closed -$1.81M – 58
2020
Q2 		$1.81M Sell
15,000
-79,000
-84% -$8.89M 0.78% 32
2020
Q1 		$8.91M Sell
94,000
-67,195
-42% -$6.39M 4.17% 8
2019
Q4 		$14.2M Buy
161,195
+28,258
+21% +$2.49M 6.23% 5
2019
Q3 		$10.6M Buy
132,937
+124,337
+1,446% +$10M 5.88% 5
2019
Q2 		$671K Buy
+8,600
New +$804K 0.34% 36

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Prosight Management's UTHR Position: Q3 2020 in Review

Prosight Management sold out of United Therapeutics (UTHR) in Q3 2020, closing a stake of 15,000 shares — an estimated $1.81M sold.

Prosight Management first reported a position in UTHR in Q2 2019 and held it in 5 quarters. The position peaked at $14.2M in Q4 2019. 332 funds tracked by Wall St. Rank hold UTHR as of Q3 2020.

  • Prosight Management reported no remaining United Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Prosight Management sold 15,000 United Therapeutics shares in Q3 2020, an estimated $1.81M.
  • Prosight Management first reported a position in United Therapeutics in Q2 2019 and held it in 5 quarters.
  • Prosight Management's United Therapeutics position peaked at $14.2M in Q4 2019.
  • 332 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2020.

Based on Prosight Management's 13F filing for Q3 2020, filed 13 Nov 2020.